Valneva SE
VALN9.490USD
+0.160+1.71%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
1.54B시가총액
손실P/E TTM
자세한 내용은 Valneva SE 회사
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE 정보
종목 코드 VALN
회사 이름Valneva SE
상장일Jun 28, 2007
CEOLingelbach (Thomas)
직원 수- -
유형Depository Receipt
회계 연도 종료Jun 28
주소6, Rue Alain Bombard
도시SAINT-HERBLAIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가France
우편 번호44800
전화33228073710
웹사이트https://valneva.com/
종목 코드 VALN
상장일Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
지역별USD
이름
수익
비율
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
기타
34.91M
20.58%
사업별
지역별
사업별USD
이름
수익
비율
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
기타
93.97%
주주
주주
비율
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
기타
93.97%
주주 유형
주주
비율
Venture Capital
2.73%
Private Equity
2.67%
Investment Advisor
0.46%
Research Firm
0.22%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.02%
기타
93.86%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
32
5.28M
6.15%
+519.56K
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Novo Holdings A/S
2.35M
2.73%
-30.00K
-1.26%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
2.29M
2.67%
+833.33K
+57.14%
Sep 30, 2025
General American Investors Company, Inc.
354.36K
0.41%
--
--
Sep 30, 2025
Wells Fargo Advisors
153.99K
0.18%
-91.19K
-37.19%
Sep 30, 2025
Marshall Wace LLP
31.21K
0.04%
+31.21K
--
Sep 30, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
--
--
Sep 30, 2025
Morgan Stanley & Co. International Plc
22.77K
0.03%
+16.23K
+248.03%
Sep 30, 2025
Citadel Advisors LLC
16.41K
0.02%
-19.33K
-54.08%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
10.20K
0.01%
+8.72K
+589.93%
Sep 30, 2025
J.P. Morgan Securities LLC
10.18K
0.01%
+10.18K
--
Sep 30, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
